The neuropathological effects of antipsychotic drugs

Schizophrenia Research

Volumn 40, Issue 2, 1999, Pages 87-99

  Harrison, Paul J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Morphometry; Neuroleptic; Neuropathology; Schizophrenia; Synapse

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PERPHENAZINE ENANTHATE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AUTOPSY; CAUDATE NUCLEUS; CELL LOSS; DRUG MECHANISM; ELECTRIC SHOCK; GLIOSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; MORPHOMETRICS; MOTOR DYSFUNCTION; NERVE CELL LESION; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REVIEW; SCHIZOPHRENIA; SYNAPSE; TARDIVE DYSKINESIA; ULTRASTRUCTURE;

EID: 0032719083     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00065-1     Document Type: Article

References (93)

1. Akai K., Roizin L., Liu J.C. Ultrastructural findings of the central nervous system in lithium neurotoxicology. Roizin L., Shiraki H., Grcevic N. Neurotoxicology. 1977;185-203 Raven, New York.
2. Arnold S.E., Trojanowski J.Q., Gur R.E., Blackwell P., Han L.-Y., Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch. Gen. Psychiatry. 55:1998;225-232.
3. Baldessarini R.J., Hegarty J.D., Bird E.D., Benes F.M. Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Am. J. Psychiatry. 154:1997;861-863.
4. Benes F.M., Paskevich P.A., Domesick V.B. Haloperidol-induced plasticity of axon terminals in rat substantia nigra. Science. 221:1983;969-971.
5. Benes F.M., Paskevich P.A., Davidson J., Domesick V.B. The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res. 329:1985;265-274.
6. Benes F.M., Paskevich P.A., Davidson J., Domesick V.B. Synaptic re-arrangements in medial prefrontal cortex of haloperidol-treated rats. Brain Res. 348:1985;15-20.
7. Calverley R.K.S., Jones D.G. Contributions of dendritic spines and perforated synapses to synaptic plasticity. Brain Res. Rev. 15:1990;215-249.
8. Casey D.E. Tardive dyskinesia. Pathophysiology. Bloom F.E., Kupfer D.J. Psychopharmacology: the Fourth Generation of Progress. 1995;1497-1502 Raven, New York.
9. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nucleus volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry. 151:1994;1430-1436.
10. Chakos M.H., Lieberman J.A., Alvir J., Bilder R., Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet. 345:1995;456-457.
11. Chakos M.H., Shirakawa O., Lieberman J., Lee H., Bilder R., Tamminga C.A. Striatal enlargement in rats chronically treated with neuroleptics. Biol. Psychiatry. 44:1998;675-684.
12. Christensen E., Moller J.E., Faurbye A. Neuropathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatrica Scand. 46:1970;14-23.
13. Clarke N.A., Webster M.-T., Francis P.T., Procter A.W., Hodgkiss A.D., Bowen D.M. β-Amyloid precursor protein-like immunoreactivity can be altered in humans by drugs affecting neurotransmitter function. Neurodegeneration. 2:1993;243-248.
14. Corsellis J.A.N. Mental Illness and the Ageing Brain. 1962;76 Oxford University Press, London.
15. Dawirs R.R., Hildebrandt K., Teuchert-Noodt G. Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J. Neural Transm. 105:1998;317-327.
16. Devenand D.P., Dwork A.J., Hutchinson E.R., Bolwig T.G., Sackeim H.A. Does ECT alter brain structure? Am. J. Psychiatry. 151:1994;957-970.
17. Doraiswamy P.M., Tupler L.A., Krishnan K.R.R. Neuroleptic treatment and caudate plasticity. Lancet. 345:1995;734-735.
18. Eastwood S.L., Burnet P.W.J., Harrison P.J. Striatal synaptophysin expression and haloperidol-induced synaptic plasticity. NeuroReport. 5:1994;677-680.
19. Eastwood S.L., Burnet P.W.J., Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience. 66:1995;309-319.
20. Eastwood S.L., Heffernan J., Harrison P.J. Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Mol. Psychiatry. 2:1997;322-329.
21. Elkashef A.M., Buchanan R.W., Gellad F., Munson R.C., Breier A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. Am. J. Psychiatry. 151:1994;752-755.
22. Enns M., Peeling J., Sutherland G.R. Hippocampal neurons are damaged by caffeine-augmented electroshock seizures. Biol. Psychiatry. 40:1996;642-647.
23. Feldman R.S., Meyer J.S., Quenzer L.F. Principles of Neuropsychopharmacology. 1997;Sinauer Associates, Sunderland, MA.
24. Fog R., Pakkenberg H., Juul P., Jorgensen O.S., Andersen J. High dose treatment of rats with perphenazine enanthate. Psychopharmacology. 50:1976;305-307.
25. Genisman Y., Morrell F., DeToledo-Morrell L. Perforated synapses on double-headed dendritic spines: a possible structural substrate of synaptic plasticity. Brain Res. 480:1989;326-329.
26. Gerlach J. Long-term effect of perphenazine on the substantia nigra in rats. Psychopharmacology. 45:1975;51-54.
27. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry. 155:1998;1711-1717.
28. Harrison P.J. Schizophrenia and its dementia. Esiri M.M., Morris J.H. The Neuropathology of Dementia. 1997;383-395 Cambridge University Press, Cambridge.
29. Harrison P.J. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain. 122:1999;593-624.
30. Higaki J., Murphy G.M. Jr., Cordell B. Inhibition of β-amyloid formation by haloperidol: a possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. J. Neurochem. 68:1997;333-336.
31. Holt D.J., Graybiel A.M., Hyde T.M., Herman M.M., Kleinman J.E., German D.C., Saper C.B. Decreased density of cholinergic interneurons in the striatum of schizophrenics. Soc. Neurosci. Abstr. 20:1994;784.
32. Ihara Y., Sato M., Otsuki S., Kaiya H., Namba M. Morphological changes in rat striatal boutons after chronic methamphetamine and haloperidol treatment. Neurosci. Res. 3:1986;403-410.
33. Jellinger K. Neuropathologic findings after neuroleptic long-term therapy. Roizin L., Shiraki H., Grcevic N. Neurotoxicology. 1977;25-42 Raven Press, New York.
34. Jellinger K.A., Gabriel E. No increased incidence of Alzheimer's disease in elderly schizophrenics. Acta Neuropathol. 97:1999;165-169.
35. Jeste D.V., Lohr J.B., Manley M. Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology. 106:1992;154-160.
36. Jeste D.V., Lohr J.B., Eastham J.H., Rockwell E., Caligiuri M.P. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J. Psychiatr. Res. 32:1998;201-214.
37. Jorgensen O., Bolwig T.G. Synaptic proteins after electroconvulsive stimulation. Science. 205:1979;705-707.
38. Kelley J.J., Gao X.M., Tamminga C.A., Roberts R.C. The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp. Neurol. 146:1997;471-478.
39. Kerns J.M., Sierens D.K., Kao L.C., Klawans H.L., Carvey P.M. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin. Neuropharmacol. 15:1992;488-500.
40. Keshavan M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., Pettegrew J.W. Changes in caudate volume with neuroleptic treatment. Lancet. 344:1994;1434.
41. Kitayama I., Yaga T., Kayahara T., Nakano K., Otani M., Nomura J. Long-term stress degenerates, but imipramine regenerates, noradrenergic axons in the rat cerebral cortex. Biol. Psychiatry. 42:1997;687-696.
42. Klintzova A.J., Haselhorst U., Uranova N.A., Schenk H., Istomin V.V. The effects of haloperidol on synaptic plasticity in rat's medial prefrontal cortex. J. Hirnforsch. 30:1989;51-57.
43. Kroesen S., Marksteiner J., Mahata S.K., Mahata M., Fischer-Colbrie R., Saria A., Kapeller I., Winkler H. Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain. Neuroscience. 69:1995;881-891.
44. Kung L., Conley R., Chute D.J., Smialek J., Roberts R.C. Synaptic changes in the striatum of schizophrenic cases: a controlled postmortem ultrastructural study. Synapse. 28:1998;125-139.
45. Kung L., Roberts R.C. Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse. 31:1999;67-75.
46. Licht R.W., Larsen J.O., Smith D., Bræligndgaard H. Effect of chronic lithium treatment with or without haloperidol on number and sizes of neurons in rat neocortex. Psychopharmacology. 115:1994;371-374.
47. Lidow M.S., Williams G.V., Goldman-Rakic P.S. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci. 19:1998;136-140.
48. Madsen A.L., Keiding N., Karle A., Esbjerg S., Hemmingsen R. Neuroleptics in progressive structural brain abnormalities in psychiatric illness. Lancet. 352:1998;784-785.
49. Mahadik S.P., Laev H., Korenovsky A., Karpiak S.E. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol. Psychiatry. 24:1988;199-217.
50. Marin C., Tolosa E. Striatal synaptophysin levels are not indicative of dopaminergic supersensitivity. Neuropharmacology. 36:1997;1115-1117.
51. Meshul C.K., Casey D.E. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res. 489:1989;338-346.
52. Meshul C.K., Tan S.E. Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity. Synapse. 18:1994;205-217.
53. Meshul C.K., Janowsky A., Casey D.E., Stallbaumer R.K., Taylor B. Coadministration of haloperidol and SCH-23390 prevents the increase in 'perforated' synapses due to either drug alone. Neuropsychopharmacology. 7:1992;285-293.
54. Meshul C.K., Stallbaumer R.K., Taylor B., Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648:1994;181-195.
55. Meshul C.K., Stallbaumer R.K., Allen C. GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat. Psychopharmacology. 121:1995;461-469.
56. Meshul C.K., Bunker G.L., Mason J.N., Allen C., Janowsky A. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J. Neurochem. 67:1996;1965-1973.
57. Meshul C.K., Andreassen O.A., Allen C., Jorgensen H.A. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology. 125:1996;238-247.
58. Meshul C.K., Buckman J.F., Allen C., Riggan J.P., Feller D.J. Activation of corticostriatal pathway leads to similar morphological changes observed following haloperidol treatment. Synapse. 22:1996;350-361.
59. Mijnster M.J., Ingham C.A., Meredith G.E., Doctor G.J., Arbuthnott G.W. Morphological changes in met5-enkephalin-immunoreactive synaptic boutons in the rat neostriatum after haloperidol decanoate treatment. Eur. J. Neurosci. 8:1996;716-726.
60. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry. 34:1993;713-738.
61. Murphy G.M. Jr., Lim K.O., Wieneke M., Ellis W.G., Forno L.S., Hoff A.L., Nordahl T. No neuropathologic evidence for an increased frequency of Alzheimer's disease among elderly schizophrenics. Biol. Psychiatry. 43:1998;205-209.
62. Nakahara T., Nakamura K., Tsutsumi T., Hashimoto K., Hondo H., Motomura K., Uchimura H. Effect of chronic haloperidol treatment on synaptic protein mRNAs in the rat brain. Mol. Brain Res. 61:1998;238-242.
63. Nakamura S. Antidepressants induce regeneration of catecholaminergic axon terminals in the rat cerebral cortex. Neurosci. Lett. 111:1990;64-68.
64. Nielsen C.B., Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology. 59:1978;85-89.
65. Oorschot D.E. Are you using neuronal densities, synaptic densities or neurochemical densities as your definitive data? There is a better way to go. Prog. Neurobiol. 34:1994;233-247.
66. Orzi F., Zoli M., Passarelli F., Ferraguti F., Fieschi C., Agnati L.F. Repeated electroconvulsive shock increases glial fibrillary acidic protein, ornithine decarboxylase, somatostatin and cholecystokinin immunoreactivities in the hippocampal formation of the rat. Brain Res. 533:1990;223-231.
67. Pakkenberg B. What happens in the leucotomised brain? A post-mortem morphological study of brains from schizophrenic patients. J. Neurol. Neurosurg. Psychiatry. 52:1989;156-161.
68. Pakkenberg H., Fog R., Nilakantan B. The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observations. Psychopharmacologia (Berl.). 29:1973;329-336.
69. Pei Q., Burnet P.W.J., Zetterström T.S.C. Changes in mRNA abundance of microtubule-associated proteins in the rat brain following electroconvulsive shock. NeuroReport. 9:1998;391-394.
70. Peters A., Palay S.L. The morphology of synapses. J. Neurocytol. 25:1996;687-700.
71. Plum F. Prospects for research on schizophrenia. Neuropathological findings. Neurosci. Res. Prog. Bull. 10:1972;384-388.
72. Purohit D.P., Perl D.P., Haroutunian V., Powchik P., Davidson M., Davis K.L. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia. Arch. Gen. Psychiatry. 55:1998;205-211.
73. Roberts R.C., Gaither L.A., Gao X.M., Kashyap S.M., Tamminga C.A. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse. 20:1995;234-243.
74. Roberts R.C., Gaither L.A., Peretti F.J., Lapidus B., Chute D.J. Synaptic organization of the human striatum: a postmortem ultrastructural study. J. Comp. Neurol. 374:1996;523-534.
75. Roberts R.C., Conley R., Kung L., Peretti F.J., Chute D.J. Reduced striatal spine size in schizophenia: a postmortem ultrastructural study. NeuroReport. 7:1996;1214-1218.
76. Rocha E., Rodnight R. Chronic administration of lithium chloride increases immunodetectable glial fibrillary acidic protein in the rat hippocampus. J. Neurochem. 63:1994;1582-1584.
77. Rocha E., Achaval M., Santos P., Rodnight R. Lithium treatment causes gliosis and modifies the morphology of hippocampal astrocytes in rats. NeuroReport. 9:1998;3971-3974.
78. Roizin L. Histopathologic observations in schizophrenia (including effects of somatic and biochemical therapies). Minckler J. Pathology of the Nervous System. vol. 3:1972;2670-2677 McGraw Hill, New York.
79. Schneider J.A., Mirra S.S. Neuropathologic correlates of persistent neurologic deficit in lithium intoxication. Ann. Neurol. 36:1994;928-931.
80. See R.E., Chapman M.A., Meshul C.K. Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse. 12:1992;147-154.
81. Seeman P. Tardive dyskinesia dopamine receptors and neuroleptic damage to cell membranes. J. Clin. Psychopharmacol. 8:(Suppl.):1988;3S-9S.
82. Smialowska M., Bal-Klara A., Smialowski A. Chronic imipramine diminishes the nuclear size of neurons in the locus ceruleus and cingular cortex but not in hippocampus of the rat. Neuroscience. 26:1988;803-807.
83. Steward O. Electroconvulsive seizures upregulate astroglial gene expression selectively in the dentate gyrus. Mol. Brain Res. 25:1994;217-224.
84. Takeichi M. Electron microscopic morphometric studies on synaptic vesicles of long-term CPZ-administered rat striatum. Folia Psychiatr. Neurol. Jpn. 39:1985;185-192.
85. Tamminga C.A., Dale J.M., Goodman L., Kaneda H., Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology. 102:1990;474-478.
86. 2+ uptake induced by amyloid β protein (25-35) in vitro. Brain Res. 748:1997;184-188.
87. Uranova N.A., Orlovskaya D.D., Apel K., Klintzova A.J., Haselhörst U., Schenk H. Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse. 7:1991;253-259.
88. Uranova N.A., Casanova M.F., DeVaughn N.M., Orlovskawa D.D., Denisov D.V. Ultrastructural alterations of synaptic contacts and astrocytes in postmortem caudate nucleus of schizophrenic patients. Schizophr. Res. 22:1996;81-83.
89. Vincent S.L., McSparren J., Wang R., Benes F. Evidence for ultrastructural changes in cortical axo-dendritic synapses following longterm treatment with haloperidol or clozapine. Neuropsychopharmacology. 5:1991;147-155.
90. Vincent S.L., Adamec E., Sorensen I., Benes F.M. The effects of chronic haloperidol administration on GABA-immunoreactive axon terminals in rat medial prefrontal cortex. Synapse. 17:1994;26-35.
91. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology. 101:1990;431-447.
92. Wischik C.M., Edwards P.C., Lai R.Y.K., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. USA. 93:1996;11213-11218.
93. Wisniewski H.M., Constantinidis J., Wegiel J., Bobinski M., Tarnawski M. Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics. Alz. Dis. Assoc. Disord. 8:1994;211-227.